ME2 New treatment approaches for idiopathic pulmonary fibrosis

Meet the expert
Aims: To review the drug development landscape for idiopathic pulmonary fibrosis (IPF) in the light of the newly approved anti-fibrotic drugs pirfenidone and nintedanib; and to discuss the preclinical, methodological, and clinical challenges in IPF drug development.

---

How to access educational materials from mobile devices

---

New treatment approaches for IPF Luca Richeldi (Southampton, United Kingdom)